Fund moves
88 tracked managers disclosed the same change for Q1 2025. From a 13F filed Apr 17, 2025 covering holdings at Mar 31, 2025 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Mar 17, 2025 · Filed Mar 18, 2025
The CFO of Gilead Sciences sold $276K of Gilead Sciences shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$276,325
Shares × reported transaction price
34 days after results of Feb 11, 2025, 38 days before results of Apr 24, 2025
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
FDA approved Odefsey on Feb 19, 2025, 26 days before this trade.
New use approved (efficacy supplement). Active ingredient: Emtricitabine, Rilpivirine Hydrochloride, Tenofovir Alafenamide Fumarate. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +1.6% | +0.3% | +1.4% |
| 30 days | −3.0% | −9.4% | +6.4% |
| 90 days | +0.5% | +5.4% | −4.9% |
| 180 days | +4.7% | +16.5% | −11.9% |
| 365 days | +31.3% | +16.3% | +14.9% |
Past results only. Not a forecast.
Fund moves
88 tracked managers disclosed the same change for Q1 2025. From a 13F filed Apr 17, 2025 covering holdings at Mar 31, 2025 — a quarter-end snapshot, not a live trade.
Fund moves
88 tracked managers disclosed the same change for Q1 2025. From a 13F filed Apr 17, 2025 covering holdings at Mar 31, 2025 — a quarter-end snapshot, not a live trade.
Andrew D Dickinson (Chief Financial Officer) sold ~$266K of Gilead Sciences
Planned saleEvery dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.